Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745657 | 0.86 | CNR2 (0.76) | CNR2 | |
| SCHEMBL14030757 | 0.86 | RAB9A (0.53) | CNR2RAB9APOLBSMN1; SMN2KMT2A | |
| SCHEMBL14005264 | 0.79 | CNR2 (0.44) | CNR2 | |
| SCHEMBL14005256 | 0.74 | CNR2 (0.55) | CNR2 | |
| SCHEMBL14005259 | 0.72 | CNR2 (0.52) | CNR2KMT2A | |
| SCHEMBL14029902 | 0.71 | CNR2 (0.52) | CNR2KMT2A | |
| SCHEMBL14005266 | 0.70 | RAB9A (0.55) | CNR2RAB9AKMT2AKDM4E | |
| SCHEMBL4745582 | 0.70 | CNR2 (0.69) | CNR2 | |
| SCHEMBL5780667 | 0.70 | CNR2 (0.81) | CNR2 | |
| SCHEMBL5780688 | 0.70 | CNR2 (1.00) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | CCR5, CCL2, CXCR4 | CNR2 496/4885RAB9A 1363/4885POLB 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.